Centanafadine for Attention-Deficit/Hyperactivity Disorder (ADHD)

"Affirmative. Per the records hosted on clinicaltrials.gov, this healthcare study began recruiting patients since March 9th 2021 and is still ongoing as of November 14th 2022. A total of 50 participants are needed to be conscribed from 5 different sites."

"Currently, the trial is recruiting at 5 distinct medical sites located in Decatur, Las Vegas and San Antonio. Additionally, there are two other facilities available. In order to reduce travel demands, it is best that participants attend a clinic closest to them if they choose to enrol."

"Presently, there is only one clinical trial analyzing Centanafadine. This investigation has not yet progressed to the third phase of development. Although it is primarily located at Little Rock, Arkansas, five other medical sites are also conducting trials on this medication."

"Currently, the only active Centanafadine study is established across 5 cities and 1 nation. This pharmaceutical experiment was sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc., commenced in 2021 with 50 participants successfully concluding its first phase of clinical approval. Post-2021, seven additional trials were completed."

"This medicinal trial, which was initially posted on March 9th 2021, is still recruiting participants. The listing has been edited up to November 14th 2022 according to clinicaltrials.gov."

"To meet the inclusion criteria for this experiment, applicants must suffer from attention deficit disorder and be between 4 and 12 years of age. The total number of participants required is 50 individuals."

"The enrolment process for this trial involves children between the ages of 4 to 12. There are 74 studies available for minors and 31 trials suited to adults over 65 years old."

"As a Phase 1 trial, the available evidence for Centanafadine's safety and efficacy is limited. Thus, our team at Power has ranked its safety as a "1" on a scale from 1 to 3."